Skip to main content
OpenTrials

Clinical trial condition

Episodic Migraine

Explore clinical trials studying Episodic Migraine. Study availability and eligibility vary by location and protocol.

48 public trials 17 recruiting studies
Refine in advanced search Browse all conditions

Episodic Migraine trial results

Completed

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827

Conditions
Episodic Migraine
Locations
  • Axiom Research /ID# 226379 Colton, California, United States
  • Pharmacology Research Institute (PRI) - Encino (Wake) /ID# 226434 Encino, California, United States
  • Pharmacology Research Institute (PRI) - Los Alamitos (Wake) /ID# 226388 Los Alamitos, California, United States
  • Pharmacology Research Institute (PRI) - Los Alamitos (Wake) /ID# 226405 Los Alamitos, California, United States
View all 114 locations
View Trial Details
Completed

A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine

NCT03963232

Conditions
Episodic Migraine
Locations
  • Xuanwu Hospital-Capital Medical University Beijing, Beijing Municipality, China
  • Chinese PLA General Hospital Beijing, Beijing Municipality, China
  • The First Affiliated Hospital Chongqing Medical University Chongqing, Chongqing Municipality, China
  • Guangzhou First People's Hospital Guangzhou, Guangdong, China
View all 40 locations
View Trial Details
Completed

Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine

NCT03939312

Conditions
Brain Diseases, Central Nervous System Diseases, Epilepsy, +5 more
Locations
  • Synexus Clinical Research US, Inc. Chandler, Arizona, United States
  • Alea Research Phoenix, Arizona, United States
  • Central Phoenix Medical Clinic Phoenix, Arizona, United States
  • Orange Grove Family Practice Tucson, Arizona, United States
View all 113 locations
View Trial Details
Completed

A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies

NCT03096834

Conditions
Brain Diseases, Central Nervous System Diseases, Disease Attributes, +13 more
Locations
  • Novartis Investigative Site Heidelberg, Australia
  • Novartis Investigative Site Innsbruck, Austria
  • Novartis Investigative Site Vienna, Austria
  • Novartis Investigative Site Brussels, Belgium
View all 59 locations
View Trial Details
Completed

Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients

NCT03333109

Conditions
Brain Diseases, Central Nervous System Diseases, Episodic Migraine, +9 more
Locations
  • Novartis Investigative Site CABA, Buenos Aires, Argentina
  • Novartis Investigative Site CABA, Buenos Aires, Argentina
  • Novartis Investigative Site CABA, Buenos Aires, Argentina
  • Novartis Investigative Site Buenos Aires, Argentina
View all 81 locations
View Trial Details
Completed

12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine

NCT03777059

Conditions
Brain Diseases, Central Nervous System Diseases, Epilepsy, +5 more
Locations
  • Synexus Clinical Research US, Inc. Chandler, Arizona, United States
  • Advanced Research Associates Glendale, Arizona, United States
  • Alea Research Institute Phoenix, Arizona, United States
  • Barrow Neurological Institute Phoenix, Arizona, United States
View all 138 locations
View Trial Details
Completed

Study to Evaluate the Safety and Tolerability of Treatment With Atogepant 60 mg Daily for the Prevention of Migraine in Participants With Episodic Migraine

NCT03700320

Conditions
Episodic Migraine
Locations
  • Clinical Research Advantage, Inc./Simon Williamson Clinic, PC Birmingham, Alabama, United States
  • Achieve Clinical Research, LLC Birmingham, Alabama, United States
  • Synexus Clinical Research US, Inc./East Valley Family Physicians PLC Chandler, Arizona, United States
  • Synexus Clinical Research US, Inc./Desert Clinical Research, LLC Mesa, Arizona, United States
View all 112 locations
View Trial Details

Related conditions